{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:55:09Z","timestamp":1791248109787,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,12,22]],"date-time":"2010-12-22T00:00:00Z","timestamp":1292976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background and Aim:\u2002<\/jats:bold> Allopurinol potentiates azathioprine and 6\u2010mercaptopurine (6\u2010MP) by increasing 6\u2010thioguanine nucleotide (6\u2010TGN) metabolite concentrations. The outcome might also be improved by adding allopurinol in individuals who preferentially produce 6\u2010methylmercaptopurine nucleotides (6\u2010MMPN), rather than 6\u2010TGN. The aim of the present study was to investigate the effect of allopurinol on concentrations of 6\u2010MMPN and 6\u2010TGN in individuals with a high ratio of these metabolites (&gt;20), which is indicative of a poor thiopurine response.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Sixteen individuals were identified who were taking azathioprine or 6\u2010MP, and were commenced on allopurinol to improve a high 6\u2010MMPN\u2003:\u2003TGN ratio. Metabolite concentrations were compared before and after commencing allopurinol, and markers of disease control were compared.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> The addition of 100\u2013300\u2003mg allopurinol daily and thiopurine dose reduction (17\u201350% of the original dose) resulted in a reduction of the median (and range) 6\u2010MMPN concentration, from 11\u2003643 (3\u2003365\u201327\u2003832) to 221 (55\u2013844) pmol\/8\u2003\u00d7\u200310<jats:sup>8<\/jats:sup> red blood cells (RBC; <jats:italic>P<\/jats:italic>\u2003=\u20030.0005), increased 6\u2010TGN from 162 (125\u2013300) to 332 (135\u2013923) pmol\/8\u2003\u00d7\u200310<jats:sup>8<\/jats:sup> RBC (<jats:italic>P<\/jats:italic>\u2003=\u20030.0005), and reduced the 6\u2010MMPN\u2003:\u20036\u2010TGN ratio from 63 (12\u2013199) to 1 (0.1\u20134.5) (<jats:italic>P<\/jats:italic>\u2003=\u20030.0005). There was a significant reduction in steroid dose requirements at 12\u2003months (<jats:italic>P<\/jats:italic>\u2003=\u20030.04) and trends for improvement in other markers of disease control. One patient developed red cell aplasia that resolved upon stopping azathioprine and allopurinol.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> In those with a high 6\u2010MMPN\u2003:\u20036\u2010TGN ratio (&gt;20), response to thiopurine treatment might be improved by the addition of allopurinol, together with a reduced thiopurine dose and close hematological monitoring.<\/jats:p>","DOI":"10.1111\/j.1440-1746.2010.06489.x","type":"journal-article","created":{"date-parts":[[2010,8,17]],"date-time":"2010-08-17T20:12:45Z","timestamp":1282075965000},"page":"49-54","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Allopurinol might improve response to azathioprine and 6\u2010mercaptopurine by correcting an unfavorable metabolite ratio"],"prefix":"10.1111","volume":"26","author":[{"given":"Sharon J","family":"Gardiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B","family":"Gearry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Burt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Chalmers\u2010Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison G","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A M","family":"Stedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Huelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray L","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,12,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/875512259100700609"},{"key":"e_1_2_6_3_2","first-page":"386","article-title":"Allopurinol\u2013azathioprine interaction","volume":"229","author":"Boyd IW","year":"1991","journal-title":"J. Intern. Med."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809603000906"},{"key":"e_1_2_6_5_2","first-page":"130","article-title":"Allopurinol and azathioprine. Fatal interaction","volume":"2","author":"Adverse Drug Reactions Advisory Committee","year":"1980","journal-title":"Med. J. Aust."},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1983.254"},{"key":"e_1_2_6_7_2","first-page":"1283","article-title":"Effect of allopurinol on the pharmacokinetics of 6\u2010mercaptopurine (NSC 755) in cancer patients","volume":"132","author":"Coffey[GET] JJ","year":"1972","journal-title":"Cancer Res."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199606150-00023"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199606000-00002"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02583.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.11.020"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-2-199507150-00009"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.01.046"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32420"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/870981"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03782.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200406000-00016"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2005.00904.x"},{"key":"e_1_2_6_19_2","first-page":"U1324","article-title":"Measurement of thiopurine methyl transferase activity guides dose\u2010initiation and prevents toxicity from azathioprine","volume":"118","author":"Sies C","year":"2005","journal-title":"N. Z. Med. J."},{"key":"e_1_2_6_20_2","first-page":"423","article-title":"A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6\u2010mercaptopurine, cyclosporine and methotrexate","volume":"91","author":"Sandborn WJ","year":"1997","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000545"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000067"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.926"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01213011-200505000-00013"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70140-5"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3282ffda37"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.62.1.102"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500421"},{"key":"e_1_2_6_30_2","first-page":"1161","article-title":"Observations on the use of allopurinol in combination with azathiprine or mercaptopurine [letter]","volume":"22","author":"Duley JA","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.02.032"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.2010.06489.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.2010.06489.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T02:45:14Z","timestamp":1697337914000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.2010.06489.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,22]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1111\/j.1440-1746.2010.06489.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.2010.06489.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,22]]},"assertion":[{"value":"2010-12-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}